J&J Invega, paroxetine interaction data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson's schizophrenia therapy Invega (paliperidone) did not produce a drug-drug reaction when administered with the selective serotonin reuptake inhibitor paroxetine (GlaxoSmithKline's Paxil and generics), according to data presented at the American Psychiatric Association annual meeting in San Diego May 22. Sixty male patients were randomized to receive either paliperidone or paroxetine plus paliperidone. Four days after paliperidone administration, no clinically significant increases in paliperidone exposures were seen. "Drug interactions frequently occur in patients with schizophrenia because this population is often treated for multiple medical and psychiatric conditions," Johnson & Johnson Franchise Medical Leader for Psychiatry Joseph Palumbo said. Study results indicate that CYP2D6-inhibiting antidepressants can be administered with paliperidone, he said. Invega, a follow-on to J&J's Risperdal (risperidone), launched in January (1Pharmaceutical Approvals Monthly January 2007, In Brief)...